Daybreak - India commoditised Novo's blockbuster obesity drug. Novo's not flinching.

Episode Date: March 31, 2026

Semaglutide's patent just expired in India. The molecule behind Novo Nordisk's blockbuster obesity drugs, Ozempic and Wegovy, is now fair game for generic manufacturers. An 85 to 90% price drop is expected.Eli Lilly's Mounjaro had already been outselling Wegovy.For most companies, this would be the beginning of an exit. But Novo is doing the opposite. Why?Tune in.

In June 2025, a Danish pharma company landed in India with a drug that it had spent over a decade building. Novo Nordisk had created the obesity drug market almost single-handedly. Its molecule, semaglutide, was the science behind Ozmpic and Vigovi. These drugs had reshaped medicine and made Novo one of the most valuable companies in Europe. India was meant to be the next chapter. But when Novo arrived, something was off. The shelves that it had imagined for Wegovi already had a rival on them. Eli Lilly, an American farmer company, had launched Monjaro, a competing obesity drug three months earlier.

And Monjaro had taken off in India. It became the fastest drug in-in-in history to cross one-crow rupees in cumulative sales. Within six months, it was outselling Vigovi 10-1. So, Novo cut its prices, sharply by 37% within the first five months of launch. Still, the gap did not close. And then, earlier this month, the other shoe dropped. Samaglutide's patent expired in India. And the molecule that Novo had guarded for 20 years is now fair game.

Indian generic manufacturers like Dr. Reddy's, Lupin and others, had been waiting with baited breath for this day to arrive. prices for these drugs are going to fall by 85 to 90% in the country. So in the space of nine months, Novo has gone from being a market pioneer to one among many, many players. And what happened next is where the story gets quite interesting. Because Novo's response to all of this has been in motion for a long time before the patent expired. And it has very little to do with drugs. Welcome to Daybreak, a business podcast from the Ken.

I'm your host, Nick Da Sharma, and I don't chase the news cycle. Instead, every day of the week, my colleague Rachel Vargheese and I will come to you with one business story that is worth understanding and worth your time. Today is Tuesday, the 31st of March. Novo had every structural advantage going in. It entered the GLP1 drug space in 2010 with Wictosa, a diabetes injectable. And that is a 12-year head start on. Eli Lilly. Head starts, however, do have a way of being overtaken. When Eli Lilly launched Monjaro globally in 2022, it came with stronger clinical trial results and a faster supply ramp

up. It priced aggressively and when it came to India, it moved very fast, arriving three months before Vigovi and snatching the first mover advantage Novo had been counting on. A farmer industry expert described Novo's pricing situation quite bluntly to my colleague the Ken reporter Soudesha Ray. They said the market had spoken and it hadn't chosen Vigovi at its original price point. Novo's revenue numbers told the same story. OZempex global revenue growth slowed from 15% in the second quarter of 2025 to just 3% in the third quarter. And Vigo's growth dropped from 67% to 18% in the same.

period. With the patent expiry now here, Novo has tried several moves to protect its position. In November 2025, it partnered with the Pune-based M-Cure pharmaceuticals to distribute a version of V-Govi under a new brand called Povistra. In February, it gave Abbott rights to sell Ozempic in India under the name Extensio. These are essentially Novo's ways of participating in the volume game. Selling a cheaper version, through partners while keeping its premium brand intact. It also partnered with HealthyFiMe, which is a weight management app that connects patients to doctors

who can prescribe GLP1 medication. The idea? An integrated platform combining drug therapy, lifestyle coaching and nutrition support that could keep patients on treatment for longer because obesity drug drop-off rates are quite high. Because, again, cost plays a role. And so do side effects.

and the difficulty of sustaining lifestyle changes. But there is a catch. Healthify Me currently lists Eli Lilly's manjaro alongside Vigovi. It is also open to partnering with other generic manufacturers as well. So even here, Novo shares the table. The drug battle, at least for now, is a difficult one to hold grounded. And Novo seems to know it. Here is where its story pivots.

from a pharma company defending market share to an investor quietly building a long-term position in Indian healthcare. To find out more, stay tuned. Novo Holdings, the investment arm that controls roughly 77% of Novo Nordisk, has been on a shopping spree. India's private hospital sector grows at about 12% annually. Profit margins hover around 22%. And private equity firms have recorded an internal rate of return of 21% over 10 years, outperforming the BSE Healthcare Index itself. For global investors, Indian hospitals, offers something quite rare,

which is basically biotech level returns in a market that is still expanding. Novo Holdings has noticed this. Its investment ticket sizes in India have grown four to five times in the last four years, approaching $100 million. The biggest move came in 2024, when it got a minority stake in Manipal hospitals, the second largest hospital chains in India, which is valued at roughly $13 billion as of July 2025. Even a 2 to 3% stake in Manipal would translate to around $390 million in value.

That deal was Nova Holdings' largest investment in Asia that year. And then, in January this year, 26, it acquired a 49% stake in Syria, A single specialty chain in Western India focused on women and children. Single specialty hospitals are acid light. They break even in around 18 months compared to 5 to 7 years for multi-specialty hospitals and their margins can reach up to 40%. There's also a specific clinical angle to the Suria bet. One in six pregnant women in India develop gestational diabetes annually.

And that is a patient population that sits in. squarely within Novo's wider drug portfolio, insulin, GLP1 therapies and beyond. Apart from hospitals, Novo Holdings has backed Cure AI and AI diagnostics platform now valued at over $260 million. It has also invested $100 million across two tranches in Med Genome, a genetic testing company that now reports about $45 million in revenue. And in 2024, it took a 6% pre-IPO stake in Mediasist, which is India's largest health insurance third-party administrator. A healthcare professional with two decades in hospital finance put it quite plainly to sedationa. They said these investments touch different points of a patient's healthcare journey, and that is the point.

You see, Novo cannot force doctors in hospitals that it co-ons to prescribe its drugs. That is just not how hospital medicine works. But it can be present at every stage. Diagnostics, treatment, insurance, follow-up care. A former Novo Nordisk employee offered a measured take on the generics threat. They said new manufacturers still have to prove quality and publish clinical work. Innovators typically retain a proportional share of the market. The collapse of Novo's drug business in India remains an open question.

But the deeper signal here is this. Novo is building for a future where the drug alone may not be enough. The obesity market is being commoditized. The real game now is owning the infrastructure around it, the hospitals, the data, the patient relationship. In India, that infrastructure is still being built. And Novo Goldings is buying into it piece by piece. Daybreak is produced from the newsroom of the Ken,

India's first subscriber-focused business news platform. What you're listening to is just a small sample of a subscriber-only offerings and a full subscription offers daily, long-form feature stories, newsletters, and a whole bunch of premium podcasts. To subscribe, head to the ken.com and click on the red subscribe button on the top of the website. Today's episode was hosted and produced by my colleague, Snitha Sharma, and edited by Radif CN.